Terms: = Lung cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Clinical Outcome
15 results:
1. Strategies Towards Improving clinical outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS; Hofland J; de Herder WW; Brabander T
Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
[TBL] [Abstract] [Full Text] [Related]
2. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract] [Full Text] [Related]
4. Treatment of oncogene-driven non-small cell lung cancer.
Kastelijn EA; de Langen AJ; Peters BJM
Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
[TBL] [Abstract] [Full Text] [Related]
5. Histopathology of giant cell tumors of the bone: With special emphasis on fibrohistiocytic and aneurysmal bone cyst like components.
Çomunoğlu N; Kepil N; Dervişoğlu S
Acta Orthop Traumatol Turc; 2019 Jan; 53(1):35-39. PubMed ID: 30392920
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms.
Goodwin CR; Abu-Bonsrah N; Rhines LD; Verlaan JJ; Bilsky MH; Laufer I; Boriani S; Sciubba DM; Bettegowda C
Spine (Phila Pa 1976); 2016 Oct; 41 Suppl 20():S218-S223. PubMed ID: 27488299
[TBL] [Abstract] [Full Text] [Related]
7. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
[TBL] [Abstract] [Full Text] [Related]
8. Role of imaging in the diagnosis of diffuse and interstitial lung diseases.
Oikonomou A
Curr Opin Pulm Med; 2014 Sep; 20(5):517-24. PubMed ID: 25050863
[TBL] [Abstract] [Full Text] [Related]
9. Novel drugs against non-small-cell lung cancer.
Pirker R
Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
[TBL] [Abstract] [Full Text] [Related]
10. One-stage total en bloc sacrectomy: a novel technique and report of 9 cases.
Guo W; Tang X; Zang J; Ji T
Spine (Phila Pa 1976); 2013 May; 38(10):E626-31. PubMed ID: 23392420
[TBL] [Abstract] [Full Text] [Related]
11. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract] [Full Text] [Related]
12. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract] [Full Text] [Related]
13. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract] [Full Text] [Related]
14. Meningioma: an update.
Lusis E; Gutmann DH
Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
[TBL] [Abstract] [Full Text] [Related]
15. Vertebral body replacement with a ceramic prosthesis for metastatic spinal tumors.
Hosono N; Yonenobu K; Fuji T; Ebara S; Yamashita K; Ono K
Spine (Phila Pa 1976); 1995 Nov; 20(22):2454-62. PubMed ID: 8578398
[TBL] [Abstract] [Full Text] [Related]
